Tumor-infiltrating lymphocytes and immune checkpoint proteins such as PD-L1 are potential prognostic factors and therapeutic targets in breast cancer. Most studies characterizing the breast tumor immune microenvironment have focused on ductal carcinomas. Here we investigate the tumor microenvironment of primary invasive lobular carcinomas. Previously constructed tissue microarrays of 47 lobular carcinomas were labeled by immunohistochemistry for PD-L1, CD8, CD20, and FoxP3. The stromal immune infiltrate density was qualitatively scored as a percentage of tumor area: 1+ ( o5%); 2+ (5-10%); 3+ (10-15%); or 4+ (450%). The average immune cell subtype per high-power field was quantitatively scored. The percentage PD-L1 labeling on tumor-infiltrating lymphocytes was scored as none, focal ( o5%), moderate (10-24%), or diffuse (50-100%). The percentage of membranous carcinoma cell PD-L1 labeling was also recorded, with o5% considered negative. All lobular carcinomas contained PD-L1 + tumor-infiltrating lymphocytes with the majority showing 1+ immune infiltrates with focal-moderate PD-L1 labeling. PD-L1 was expressed by tumor cells in 17% of lobular carcinomas. In contrast to ductal carcinomas, there was no correlation between the immune infiltrate density, the PD-L1 expression by lobular carcinoma cells, tumor grade, or the expression of estrogen receptor or human epidermal growth factor receptor-2. However, both the tumor-infiltrating lymphocyte density and the average CD8 + T-cell counts correlated with immune cell PD-L1 status (P = 0.004 and 0.03, respectively). Similar to breast ductal carcinomas, PD-L1 + lobular breast carcinomas had higher numbers of PD-L1 + tumor-infiltrating lymphocytes (63%) than PD-L1 − lobular carcinomas (23%; P = 0.04). These data show that a subset of primary breast lobular carcinomas both express PD-L1 on tumor cells and contain PD-L1 + tumor-infiltrating lymphocytes, suggesting the possibility of both constitutive and adaptive PD-L1 expression. Together, these results support immunotherapy as a potential treatment for a subset of patients with primary invasive lobular breast carcinomas. The host immune response has an important role in breast cancer progression and response to therapy. Multiple studies in invasive ductal carcinomas have demonstrated improved survival and response to neoadjuvant therapy in patients with higher numbers of intratumoral cytotoxic T cells and B cells. 1,2 Conversely, shorter progression-free and overall survival are associated with increased FoxP3 + regulatory T cells and a lower ratio of CD8 + T cells to FoxP3 + T cells. 3 Triple-negative and human epidermal growth factor receptor-2-positive (HER-2 + ) tumors show particularly strong correlations between tumor-infiltrating lymphocytes, survival,
and response to therapy. Estrogen receptor-negative (ER − ) and HER-2 + carcinomas harbor larger numbers of tumor-infiltrating lymphocytes than ER + tumors. 4 Patients with triple-negative carcinomas and high tumor-infiltrating lymphocytes have longer survival, 5, 6 decreased distant recurrence, 6, 7 and increased time to relapse. 8 Further, triple-negative carcinomas and ER − carcinomas with high tumorinfiltrating lymphocytes show improved responses to chemotherapy. 9, 10 The association of a robust immune response in breast carcinomas with survival and treatment response suggests that enhancing the antitumor immune response may improve outcomes. Of particular interest is using immune checkpoint blockade, especially blockades targeting the pathway governed by programmed cell death protein-1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1). 11, 12 PD-1 (B7-1) is a member of the B7-CD28 family of co-stimulatory molecules and primarily binds to PD-L1 and PD-L2, which are inducible on the surface of tumor cells and tumor-infiltrating immune cells by interferon-γ (IFN-γ) and other cytokines. 13 In immune responses to infection, the PD-1/PD-L1 pathway serves as a feedback mechanism to prevent excessive T-cell activity and autoimmunity. However, in malignancy, PD-L1 upregulation in the tumor microenvironment counterregulates the antitumor immune response and can prevent effective antitumor immunity. PD-L1 is expressed on invasive breast carcinoma cells and their associated immune infiltrates. [14] [15] [16] PD-L1 expression in breast carcinomas is associated with a higher number of tumor-infiltrating lymphocytes, ER negativity, and poor chemotherapy response. 17 We previously reported PD-L1 labeling and patterns of tumor-infiltrating lymphocytes across the continuum from in situ, invasive, and metastatic ductal carcinomas. In both in situ and invasive ductal carcinomas, we observed more brisk lymphocytic infiltrates with more extensive PD-L1 labeling in ER − tumors than in ER + tumors. 12, 18, 19 PD-L1 labeling by invasive ductal carcinoma cells was also enhanced in ER − tumors. 12, 18 Previous studies have focused almost exclusively on invasive ductal carcinomas, with limited attention to the microenvironment of special subtypes of breast carcinoma. Recent molecular studies suggest a role for the immune microenvironment in some lobular carcinomas, which are the most common special histologic subtype of breast cancer. Two distinct molecular signatures of lobular carcinomas have been described: 'hormone related,' showing epithelial to mesenchymal transition, active ER and PR signaling, gains of chromosomes 1q and 8q, and loss of 11q; and 'immune related,' showing upregulated expression of PD-L1, PD-1, and CTLA-4 genes, high levels of expression of CD4 and CD8, cytokine and chemokine signaling pathways, and increased sensitivity to DNA-damaging agents. 20 In addition, lobular carcinomas show increased B7H4 protein expression, 21 increased PDL1 mRNA expression, 22 and an association between B7H3 expression, IL-10 expression, and advanced stage. 23 These findings suggest a potential role for immune suppression and immune resistance in a subset of lobular carcinomas.
Despite these findings, data characterizing the immune microenvironment of lobular carcinoma are limited. Here we profile the tumor-infiltrating lymphocyte composition and PD-L1 labeling patterns of 47 cases of primary invasive lobular carcinomas with defined ER, PR, and HER-2 status to explore whether a subset might display a similar inflamed immune microenvironment as their ductal counterparts.
Materials and methods

Case Selection and Tissue Microarray Construction
We constructed tissue microarrays (1.4 mm cores, 5-10 cores per tumor that included a portion of adjacent normal tissue) from archived paraffin tissue blocks of 47 cases of primary infiltrating lobular carcinoma and associated lobular carcinoma in situ or atypical lobular hyperplasia as previously described. 24, 25 Briefly, all cases were incident lobular carcinomas surgically resected at our institution, and the morphologic impression of invasive lobular carcinoma was subsequently confirmed by loss of membranous E-cadherin labeling by immunohistochemistry at the time of diagnosis. The first 34 cases were identified as consecutive invasive lobular carcinomas, and 97% were ER + /HER-2 − . The subsequent 12 cases were selected from the archives as consecutively identified triple-negative or HER-2 + lobular carcinomas. If the primary invasive tumor was a localized mass, regions of both the periphery and center were included in the tissue microarray. Tissue microarrays were previously labeled for ER, PR, and HER-2 to subclassify cases into the following groups: ER + /PR + /HER-2 − ; triple-positive/luminal B (ER + /PR + /HER-2 + ); HER-2 + (ER − /PR − /HER-2 + ); and triple-negative (ER − /PR − /HER-2 − ). ER and PR positivity was defined as 41% nuclear labeling; HER-2 positivity was defined as 410% complete strong membranous labeling or a fluorescence in situ hybridization ratio of 42.0, as per the 2012 ASCO/CAP guidelines. Clinicopathologic data, including gender, age, race, stage, progression, and survival are summarized in Table 1 . The median follow-up was 52 months (mean, 56 months; range, 0-167 months).
Quantification of Tumor-infiltrating Lymphocytes
We scored the density of stromal tumor-infiltrating lymphocytes on the hematoxylin-and-eosin-stained sections of the tissue microarrays in a qualitative manner as the percentage stromal area occupied by mononuclear lymphocytes per the recommended scoring guidelines of the International TILs Working Group. 26, 27 The density was scored as the average stromal tumor-infiltrating lymphocytes. The scores were subdivided into the following categories: none (0); rare (1+; tumor-infiltrating lymphocytes comprising o 5% of tumor stromal area); mild (2+; tumor-infiltrating lymphocytes comprising 5-10% of tumor stromal area); moderate (3+; tumor-infiltrating lymphocytes comprising 11-49% of tumor stromal area); or brisk (4+; tumor-infiltrating lymphocytes comprising 450% of tumor stromal area).
Immunohistochemistry for Lymphocyte Subsets and PD-L1
Using immunohistochemistry, we labeled tissue microarrays for cytokeratin AE1/AE3 (catalog no. mab3412, dilution 1:4000, Chemicon, Temecula, CA, USA) and CD45 (clone PD7/26+2b1, catalog no. m0701, Dako, Carpintera, CA, USA) to highlight the carcinoma cell and lymphocyte populations, respectively. Tumor-infiltrating lymphocyte subsets were identified by immunohistochemical labeling for CD8 (mouse monoclonal, clone C8/C8144B, catalog no. 760-4250, Cell Marque, Rockin, CA, USA), CD20 (monoclonal, clone MS/L26, catalog no. 760-2531, Ventana Medical Systems, Tucson, AZ, USA), and FoxP3 (mouse monoclonal, clone 236A/E7, catalog no. 14-4777-80, dilution 1:50, eBioscience, San Diego, CA, USA) as previously described. 12, 19 We defined CD8 and CD20 expression as membranous lymphocyte cell labeling, and FoxP3 expression as nuclear lymphocyte cell labeling. We manually counted the number of CD8, CD20, and FoxP3 cells per one high-power field for each core and averaged each across cores from the same case of invasive lobular carcinoma. Each high-power field was chosen as representative of the overall tumor lymphocytic infiltration in the core.
We labeled tissue microarrays for PD-L1 (B7-H1) using the rabbit monoclonal anti-human PD-L1 antibody, SP142 (Spring Bioscience, Pleasanton, CA, USA). 28 PD-L1 labeling was scored by two pathologists (EDT and ACM) blinded to patient clinicopathologic characteristics, and discrepancies were adjudicated by a third pathologist (JMT). We scored the percentage invasive lobular carcinoma cells with clear membranous PD-L1 labeling in 5% increments, with any intensity labeling 45% considered positive. We scored the percentage PD-L1 labeling by tumor-infiltrating lymphocytes as none (0), focal (1; o 5%), moderate (2; 6-49%), or diffuse (3; 50-100%). The PD-L1 labeling by carcinoma cells and TIL was scored as an average across all tissue microarray spots. 
Death due to disease
Abbreviations: HER-2, human epidermal growth factor 2; LCIS, lobular carcinoma in situ.
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Statistical Analysis
We performed statistical analysis using paired, two-tailed Student's t-test and the Fisher's exact test.
Results
Tumor-Infiltrating Lymphocytes Correlate with Patient Age and Race in Invasive Lobular Carcinoma
We first evaluated the density and composition of immune infiltrates associated with invasive lobular carcinomas. All tumors in our series contained tumorinfiltrating lymphocytes (Figure 1a ). The majority (53%) showed 1+ infiltrates, and 32% and 15% contained 2+ and 3+ infiltrates, respectively. No invasive lobular carcinoma had 4+ brisk lymphocytic infiltration (defined as 450% tumor stroma area). The average CD8 count per high-power field increased correspondingly across tumors with 1+, 2 +, and 3+ qualitative tumor-infiltrating lymphocyte scores (from 23 to 40 to 88 CD8 + cells per high-power field, respectively; Po0.0002). Associated regions of atypical lobular hyperplasia or lobular carcinoma in situ also showed tumor-infiltrating lymphocytes, both within the in situ lesions and at the interface between in situ lesion and normal breast and/or adjacent invasive lobular carcinoma (Figure 1b) . Patients with 3+ tumor-infiltrating lymphocytes were younger (mean age, 46 years) than patients with 1+/2+ tumor-infiltrating lymphocytes (mean age, 62 years; P = 0.001; Table 2 ). By qualitative assessment on hematoxylin and eosin sections, invasive lobular carcinomas in Black patients had fewer tumorinfiltrating lymphocytes (100% with 1+ lymphocytes) than invasive lobular carcinomas in White patients (46% with 1+ lymphocytes; P = 0.049); there was a trend toward higher individual CD8 and CD20 cell counts and higher CD8/FoxP3 ratios in tumors from Black patients compared to White patients (P = 0. 
PD-L1 Expression by Tumor-infiltrating Lymphocytes Correlates with the Overall Degree of Lymphocyte Infiltration
We next assessed PD-L1 expression on stromal tumor-infiltrating lymphocytes. All invasive lobular carcinomas contained PD-L1 + tumor-infiltrating lymphocytes, with 71% displaying focal or moderate labeling, and 29% displaying diffuse labeling (ie, 450% tumor-infiltrating lymphocytes labeling for PD-L1; Table 2 ). Tumors with greater numbers of We next assessed the relationship between tumor cell PD-L1 expression and the degree of lymphocyte infiltration and lymphocyte PD-L1 expression. In contrast to the observed associations in ductal breast carcinomas, there was no correlation between PD-L1 labeling on the lobular carcinoma tumor cells and the density of the overall lymphocyte infiltrate, or with either the lobular carcinoma grade or ER/HER-2 status (Figure 2 ). However, there was a correlation between tumor cell PD-L1 labeling and the proportion of PD-L1 + lymphocytes in the tumor microenvironment, such that 63% of lobular carcinomas with PD-L1 + tumor cells contained a high proportion of PD-L1 + lymphocytes compared to 23% of lobular carcinomas with PD-L1 − tumor cells (P = 0.04). Taken together, these data support both constitutive and adaptive PD-L1 expression within the lobular breast carcinoma immune microenvironment. 
Discussion
Our data demonstrate several important characteristics of the immune milieu in invasive lobular breast carcinoma. First, all lobular carcinomas in this cohort contained tumor-infiltrating lymphocytes, with a subset showing a high proportion of PD-L1 + lymphocytes. Second, a subset of invasive lobular carcinomas (17%) shows expression of PD-L1 by lobular carcinoma cells. Similar to ductal carcinoma in situ, lobular carcinoma in situ/atypical lobular hyperplasia, when present, also harbors an associated immune infiltrate that tends to reflect the PD-L1 labeling pattern of the associated invasive lobular carcinoma. In contrast to our previous studies of invasive ductal carcinomas, we found no correlation between carcinoma cell PD-L1 labeling and the overall density of the lymphocyte infiltration, ER status, HER-2 status, or tumor grade of the invasive lobular carcinomas. However, we did find that PD-L1 labeling on invasive lobular carcinomas correlates with a higher proportion of PD-L1 + tumor-infiltrating lymphocytes, and that the presence of higher numbers of PD-L1 + tumor-infiltrating lymphocytes correlates both with the overall degree of lymphocytic infiltration and with higher CD8 + T-cell counts. Our study highlights distinct differences between the immune microenvironment of invasive ductal carcinomas and invasive lobular carcinomas of the breast. We and others have shown a correlation between increasing density of tumor-infiltrating lymphocytes and ER negativity in both invasive 4, 17 and in situ ductal carcinoma. 19 PD-1/PD-L1 expression on both tumor-infiltrating lymphocytes and tumor cells is also higher in ER − ductal carcinomas than in ER + ductal carcinomas. 15, 17, 29 In contrast, in our cohort of invasive lobular carcinomas, there was no association between tumor-infiltrating lymphocyte density or hormone receptor status and the PD-L1 labeling in carcinoma cells. In one prior study, CD4 + , FoxP3 + , and IL-17 + tumor-infiltrating lymphocytes in invasive breast carcinomas were increased in ductal carcinomas as compared to lobular carcinomas, and were associated with ER negativity in ductal but not in lobular tumors. 30 This report is consistent with our observation that the lymphocyte density and tumor cell PD-L1 labeling in lobular carcinomas do not track together. These findings suggest that different pathways may dominate the regulation of PD-L1 expression in ductal and lobular breast carcinomas.
PD-L1 upregulation in the tumor microenvironment can occur via adaptive or constitutive pathways. In the former, expression is driven by IFN-γ and toll-like receptor signaling generated by activated immune cells, [31] [32] [33] [34] whereas constitutive expression is due to oncogenic signaling. The PD-L1/PD-1 pathway serves as one of the multiple mechanisms of immune regulation to restrain immune responses and regulate their propagation. The induction of PD-L1 expression within tumors has been termed adaptive immune resistance, reflecting the ability of tumors to escape the active antitumor immune response through upregulation of the PD-1 immune checkpoint pathway in response to inflammatory stimuli. 35 Adaptive immune resistance has been described in an array of tumors, including melanoma, Merkel cell carcinoma, non-small-cell lung cancers, and breast carcinoma. 4, [35] [36] [37] Most prior studies in ductal carcinomas of the breast support a dominant role for adaptive pathways of PD-L1 expression, in which highly inflamed tumors, enriched for those lacking ER expression, demonstrate the highest rates of PD-L1 expression on both tumor cells and tumor-infiltrating lymphocytes. In contrast, in our study of primary lobular carcinomas, tumor-infiltrating lymphocytes of varying densities were distributed amongst ER − and ER + tumors. Diffuse PD-L1 expression by tumor-infiltrating lymphocytes was seen even in non-inflamed ER + tumors, suggesting that adaptive expression may not be the only driver of tumor cell PD-L1 upregulation in the lobular carcinoma microenvironment.
In addition to the adaptive pathway of PD-L1 upregulation, PD-L1 can also be upregulated in the tumor microenvironment via a constitutive pathway of expression related to intrinsic tumor cell mutations. The lack of correlation between PD-L1 labeling in invasive lobular carcinoma cells and the density of lymphocytic infiltration in these tumors suggests that other factors, such as oncogenic signaling via mutations intrinsic to carcinoma cells, may influence PD-L1 expression independent of cytokine modulation via tumor-infiltrating lymphocytes. Constitutive expression of PD-L1 has been reported in multiple tumor types associated with a variety of signaling pathways. 38 For example, loss of PTEN function can lead to PD-L1 upregulation in glioblastoma 39 and colorectal carcinomas 40 as a result of oncogenic mutation or microRNA inhibition, respectively. Chromosomal translocations and amplifications involving 9p24.1 lead to constitutive expression of PD-L1 in some lymphomas, 41, 42 and 9p24.1 amplification has been described in triplenegative breast carcinomas. 43 In addition, PD-L1 expression in certain T-cell lymphomas can result from signaling through the tyrosine kinase NPM-ALK via STAT3 signaling. 44 Anaplastic large-cell lymphomas and Hodgkin lymphomas can both express PD-L1 as a result of ERK activation. 45 In non-small-cell lung carcinomas, inhibition of epidermal growth factor receptor (EGFR) by erlotinib decreased PD-L1 expression in EGFR-mutated tumor cells, suggesting a possible link between EGFRmediated carcinogenesis and PD-L1 expression. 46 Links between the epithelial-mesenchymal transition and PD-L1 expression have been suggested in mouse models through alterations in E-cadherin. 46 In addition to constitutive expression, there was also evidence of adaptive PD-L1 expression. Specifically, while there was no association between overall tumor-infiltrating lymphocyte density and PD-L1 expression on tumor cells in lobular carcinoma, we did see an association between overall infiltrating immune cell density and average CD8 + cell counts and PD-L1 expression on tumorinfiltrating lymphocytes. In addition, PD-L1 + lobular carcinomas were more likely to contain PD-L1 + tumor-infiltrating lymphocytes than PD-L1 − carcinomas. Our data support at least three patterns of PD-L1 expression in the lobular breast tumor microenvironment: adaptive; constitutive; and a combination, with both adaptive immune resistance and constitutive PD-L1 expression at play within individual tumors. This combination of regulatory mechanisms governing PD-L1 expression in lobular carcinoma suggests the possibility of combinatorial therapies targeting both immune-related and intrinsic oncogenic signaling pathways of upregulation.
This study is limited by the relatively small sample size and the low number of hormone receptor-negative cases of lobular breast carcinomas, although it should be noted that the majority of invasive lobular carcinomas are hormone receptorpositive. The tissue microarray platform is further limited by tumor sampling that may not reflect potential heterogeneity within an individual primary tumor. To address these concerns, we sampled five large cores per individual tumor, roughly estimating the amount of tumor material present on a small core needle biopsy. A recent study has shown that core needle biopsies are adequate in assessing the overall tumor-infiltrating lymphocyte density in tumors. 47 In addition, the tissue microarray cores were sampled from both the periphery and center of the tumor to address any potential spatial heterogeneity. Notably, concerns about spatial heterogeneity are mitigated as most invasive lobular carcinomas infiltrate through the benign breast parenchyma in a permeative manner, such that there is rarely a distinct 'leading edge' as seen in invasive ductal carcinoma.
In conclusion, our data demonstrate an active tumor immune microenvironment in invasive lobular breast carcinomas with data supporting both adaptive and constitutive expression of PD-L1 in a pattern distinct from that seen in ductal breast carcinomas. Together with our previously published data, this study supports further exploration of the factors determining PD-L1 expression by both tumorinfiltrating lymphocytes and tumor cells in all breast cancer subtypes. It also suggests a potential role for immune checkpoint blockade therapy in primary invasive lobular carcinoma of the breast. Furthermore, our findings suggest that it may not be appropriate to use ER status, HER-2 status, or carcinoma grade to select patients for clinical trials evaluating immunotherapeutic strategies in patients with primary invasive lobular carcinoma. As invasive lobular breast carcinomas often respond less well to chemotherapy relative to ductal carcinomas, targeted immunotherapy may provide additional treatment options for a subset of patients with this histologic subtype of breast carcinoma.
